NDAInjectionInjectablePriority Review
Approved
Aug 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
Priority Review
PHOTOFRIN (porfimer sodium) by Lavipharm is 12. First approved in 2003.
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PHOTOFRIN (porfimer sodium) is a photosensitizing agent used in photodynamic therapy (PDT), a light- and oxygen-dependent treatment that generates reactive oxygen species to cause tumor cell death and vascular occlusion. It is administered intravenously followed by illumination with 630 nm wavelength laser light, creating selective tumor destruction through a combination of selective drug retention and targeted light delivery. The mechanism involves radical-mediated cellular damage and ischemic necrosis rather than thermal effects.
LOE Approaching
As LOE approaches, the brand team will likely shift focus to lifecycle extension strategies, managed care retention, and commercial wind-down planning; limited growth opportunities suggest smaller team infrastructure.
Mechanism of Action
12.1 Mechanism of Action The cytotoxic and antitumor actions of PHOTOFRIN are light and oxygen dependent. Photodynamic therapy (PDT) with PHOTOFRIN is a two-stage process. The first stage is the intravenous administration of PHOTOFRIN. Clearance from a variety of tissues occurs over 40-72 hours,…
Worked on PHOTOFRIN at Lavipharm? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.